Active Funding Opportunities:

PAR

PAR-21-247: Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial Not Allowed)

  • Application Due Dates:¬†October 1, 2021; June 15, 2022; June 15, 2023
  • Expiration Date: June 16, 2023

Notice of Special Interest (NOSI)

NOT-HG-21-018: Advancing Genomic Technology Development for Research and Clinical Application

  • Expiration Date: January 10, 2024

Inactive Funding Opportunities:

RFAs

  • RFA-HG-21-006: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial not Allowed)
  • RFA-HG-21-007: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial not Allowed)
  • RFA-HG-21-008: Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44 Clinical Trial not Allowed)
  • RFA-HG-21-001: Technology Development for Single-Molecule Protein Sequencing and Single-Cell Proteome Analysis (R01 Clinical Trial not allowed)
  • RFA-HG-21-002: Technology Development for Single-Molecule Protein Sequencing (R21 Clinical Trial not allowed)
  • RFA-HG-20-014: Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)
  • RFA-HG-20-015: Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not allowed)
  • RFA-HG-20-016: Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)
  • RFA-HG-20-019: NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)
  • RFA-HG-18-001: Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)
  • RFA-HG-18-002: Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)
  • RFA-HG-18-003: Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)

PARs

  • PAR-18-777: Novel Genomic Technology Development (R01 Clinical Trial Not Allowed)
  • PAR-18-778: Novel Genomic Technology Development (R21 Clinical Trial Not Allowed)
  • PAR-18-779: Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed)

For more funding opportunities please visit NHGRI Research Funding

Updated 02/01/2023